Pfizer settles with Novartis in Zithromax lawsuit

Share this article:

Pfizer has settled its lawsuit against Novartis for alleged infringement of the US patent for the antibiotic Zithromax (azithromycin), Bloomberg News reports.

Pfizer first sued Novartis and its Sandoz generics unit in February 2006 in federal court in Wilmington, DE.

Pfizer sought unspecified damages in the case, stating it would be “irreparably harmed” by Novartis’ use of a formulation of crystal azithromycin. Under the settlement, Pfizer and Novartis “have agreed to settle all claims” regarding the drug patent, court documents said.

The settlement is Pfizer’s second in a year related to the Zithromax patent. In November of 2006, Israel’s Teva Pharmaceutical Industries said it would pay Pfizer as much as $70 million for rights to make copies of Zithromax and cancer drug Idamycin.

Pfizer has seen sales of Zithromax nosedive as the other drugmakers, including American Pharmaceutical Partners, were able to bring their versions of azithromycin to market following the expiration of the drug’s US patent in 2005.

Branded Zithromax had $638 million in sales in 2006, down from $2 billion in 2005.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.